Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy

Documenti analoghi

• Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi‐criteria decision analysis
  di: Daniel‐Aníbal García‐Diego, et al.
  Pubblicazione: (2024)
• Differences and similarities in patient‐reported outcomes among men and women with haemophilia
  di: Christine L. Kempton, et al.
  Pubblicazione: (2024)
• Women and girls’ participation in haemophilia clinical trials
  di: Stacey A. Fedewa, et al.
  Pubblicazione: (2024)
• Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience
  di: Robert Klamroth, et al.
  Pubblicazione: (2024)
• Quality of life of siblings of adolescents with severe haemophilia (FRATHEMO): An ancillary study to the TRANSHEMO project
  di: Ngoc Anh Thu Nguyen, et al.
  Pubblicazione: (2024)